🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Finnish Pharma Firm Orion Raises Outlook After Merck Agreement

Published 07/13/2022, 06:47 AM
Updated 07/13/2022, 06:53 AM
© Reuters.

By Scott Kanowsky 

Investing.com -- Shares in Orion (HE:ORNBV) rose on Wednesday after the Finnish pharmaceutical company upgraded its annual outlook following a cancer drug manufacturing agreement with U.S. peer Merck & Company (NYSE:MRK).

In a statement, Orion said it now expects full-year operating profit and net sales to be "clearly higher" than in 2021. It previously said the results would be at similar levels to the prior year.

The raised guidance partly stems from an upfront payment of $290 million that Orion will receive under the terms of the deal, the firm added.

Orion will work with a subsidiary of Merck & Co that runs the drugmaker's business outside of the U.S. and Canada to develop a new prostate cancer treatment, known as ODM-208. The drug is currently in Phase 2 clinical trials.

“This agreement positions Orion to harness the potential of ODM-208 for the good of patients while continuing to invest in our other programs without compromising our financial targets,” said Orion president and CEO Timo Lappalainen.

Meanwhile, Merck said the partnership will enhance its existing prostate cancer drug portfolio.

The move comes as the New Jersey-based company has been looking to bolster its cancer treatments through a potential $40 billion merger with biotechnology firm Seagen (NASDAQ:SGEN), according to sources quoted by the Financial Times. Merck is aiming to reinforce its offerings before the patent of its crucial Keytruda cancer drug expires at the end of the decade, the FT reported.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.